Carson Advisory Inc. Sells 90 Shares of Eli Lilly and Company (NYSE:LLY)

Carson Advisory Inc. cut its position in Eli Lilly and Company (NYSE:LLY) by 8.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 966 shares of the company’s stock after selling 90 shares during the period. Carson Advisory Inc.’s holdings in Eli Lilly and Company were worth $563,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Lipe & Dalton purchased a new position in Eli Lilly and Company during the 4th quarter worth $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the third quarter worth about $27,000. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company during the third quarter valued at about $35,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $36,000. Finally, Family CFO Inc acquired a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

NYSE:LLY traded down $20.94 during trading hours on Friday, reaching $734.97. 4,535,213 shares of the company were exchanged, compared to its average volume of 3,087,178. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90. The stock’s 50-day moving average is $761.75 and its 200-day moving average is $670.56. The firm has a market cap of $698.52 billion, a PE ratio of 108.24, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.62 earnings per share. On average, sell-side analysts anticipate that Eli Lilly and Company will post 13.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on LLY. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price target (up previously from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday. Morgan Stanley boosted their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Finally, TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.